PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33585479-7 2021 Importantly, a miR-4680-3p-specific inhibitor normalized cell proliferation and altered expression of ERBB2 and JADE1 in cells treated with atRA. Tretinoin 140-144 erb-b2 receptor tyrosine kinase 2 Homo sapiens 102-107 33585479-8 2021 Taken together, our results suggest that upregulation of miR-4680-3p induced by atRA may cause cleft palate through suppression of ERBB2 and JADE1. Tretinoin 80-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 131-136 25631875-6 2015 ATRA treatment was associated with significantly increased Rb expression and decreased HER2 expression in gastric mucosa. Tretinoin 0-4 erb-b2 receptor tyrosine kinase 2 Homo sapiens 87-91 29899874-0 2018 Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells. Tretinoin 61-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 78-82 29899874-10 2018 Tz+RA strongly reduced FAK and HER2 expression and induced nuclear FAK translocation. Tretinoin 3-5 erb-b2 receptor tyrosine kinase 2 Homo sapiens 31-35 28592877-2 2017 In this study, we found that combination of omega-3 free fatty acids (omega-3 FFAs) and ATRA exhibited synergistic inhibition of cell growth in three subtypes (ER+ MCF7, HER2+ SK-BR-3, Triple negative HCC1806 and MDA-MB-231 cells) of human breast cancer cell lines. Tretinoin 88-92 erb-b2 receptor tyrosine kinase 2 Homo sapiens 170-174 27074819-0 2016 The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARalpha/STAT1 axis. Tretinoin 75-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 4-8 27074819-4 2016 In this study, we showed that TAK165, a HER2 inhibitor, exhibited a strong synergy with ATRA to promote AML cell differentiation. Tretinoin 88-92 erb-b2 receptor tyrosine kinase 2 Homo sapiens 40-44 26133921-3 2015 This study investigates whether combining all-trans retinoic acid (ATRA) and histone deacetylase inhibitor entinostat (ENT) can inhibit TICs and HER2 in AI-resistant cells and tumors. Tretinoin 52-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-149 26133921-3 2015 This study investigates whether combining all-trans retinoic acid (ATRA) and histone deacetylase inhibitor entinostat (ENT) can inhibit TICs and HER2 in AI-resistant cells and tumors. Tretinoin 67-71 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-149 26133921-4 2015 Modulation of cell viability and HER2 expression were assessed in AI-resistant cells treated with ATRA + ENT. Tretinoin 98-102 erb-b2 receptor tyrosine kinase 2 Homo sapiens 33-37 26133921-9 2015 Treatment with ATRA + ENT reduced HER2 expression and viability (P < 0.001) in AI-resistant cells, as well as decreased SP (P < 0.0001), mammosphere formation (P < 0.01), and expression of TIC molecular markers (P < 0.01) in LTLT-Ca. Tretinoin 15-19 erb-b2 receptor tyrosine kinase 2 Homo sapiens 34-38 31619506-7 2020 Pathway analysis implicated the MAPK13/p38delta and retinoic acid regulatory nodes, which were confirmed to display divergent responses in different HER2+ cancer lines. Tretinoin 52-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 149-153 30431066-12 2019 In addition, ethinyl targeted to TNF, whereas TNF and ERBB2 were targeted by cyclosporine, and tretinoin was a targeted chemical of ERBB2. Tretinoin 95-104 erb-b2 receptor tyrosine kinase 2 Homo sapiens 132-137 25961594-1 2015 SKBR3-cells, characterized by ERBB2/RARA co-amplification, represent a subgroup of HER2+ breast-cancers sensitive to all-trans retinoic acid (ATRA) and Lapatinib. Tretinoin 127-140 erb-b2 receptor tyrosine kinase 2 Homo sapiens 83-87 25961594-1 2015 SKBR3-cells, characterized by ERBB2/RARA co-amplification, represent a subgroup of HER2+ breast-cancers sensitive to all-trans retinoic acid (ATRA) and Lapatinib. Tretinoin 142-146 erb-b2 receptor tyrosine kinase 2 Homo sapiens 83-87 15375520-1 2004 We showed that the HER2/Grb2/Akt pathway induces all-trans retinoic acid (ATRA) resistance in breast cancer cells by suppressing the DNA binding activity of retinoic acid receptors (RAR). Tretinoin 59-72 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-23 23830798-2 2013 A patient, with chemo- and trastuzumab-resistant HER2-overexpressing breast cancer, who presented concomitant acute promyelocytic leukemia, showed a response in her breast lesions to retinoic acid, arsenic, and aracytin. Tretinoin 183-196 erb-b2 receptor tyrosine kinase 2 Homo sapiens 49-53 22056878-5 2012 In estrogen-receptor-negative cellular models showing coamplification of ERBB2 and RARA, simultaneous targeting of the corresponding gene products with combinations of lapatinib and ATRA causes synergistic growth inhibition, cyto-differentiation and apoptosis. Tretinoin 182-186 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-78 22056878-9 2012 Induction of the retinoid-dependent RARRES3 protein by ATRA stabilizes the effect of lapatinib inhibiting ERBB2 phosphorylation. Tretinoin 55-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 106-111 20696059-6 2010 RESULTS: In HER2-overexpressing/ER-positive BT474 cells, combining all-trans retinoic acid (atRA) with tamoxifen or trastuzumab synergistically inhibited cell growth, and altered cell differentiation and cell cycle. Tretinoin 77-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 12-16 20696059-6 2010 RESULTS: In HER2-overexpressing/ER-positive BT474 cells, combining all-trans retinoic acid (atRA) with tamoxifen or trastuzumab synergistically inhibited cell growth, and altered cell differentiation and cell cycle. Tretinoin 92-96 erb-b2 receptor tyrosine kinase 2 Homo sapiens 12-16 16752155-3 2007 RA treatment resulted in an increase of p21, p27 and p53 protein levels and G1 arrest in UM cells, which correlated with significant down-modulation of surface Her2/neu proto-oncogene expression. Tretinoin 0-2 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-168 15375520-1 2004 We showed that the HER2/Grb2/Akt pathway induces all-trans retinoic acid (ATRA) resistance in breast cancer cells by suppressing the DNA binding activity of retinoic acid receptors (RAR). Tretinoin 74-78 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-23 15375520-3 2004 Here, we determined whether AP-1 binding activity is correlated with ATRA resistance in HER2-overexpressing cells. Tretinoin 69-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 88-92 12595744-4 2002 At 1.3 micro M concentration (a clinically pharmacologically achievable dose), 4HPR increased ATRA sensitivity synergistically in HER2/NEU-overexpressing BT-474, MDA-MB-453, and MCF-7/Her2 breast cancer cells. Tretinoin 94-98 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 12595744-1 2002 We previously reported that overexpression of the HER2/NEU oncogene induces all-TRANS retinoic acid (ATRA) resistance in breast cancer cells. Tretinoin 76-99 erb-b2 receptor tyrosine kinase 2 Homo sapiens 50-58 12595744-1 2002 We previously reported that overexpression of the HER2/NEU oncogene induces all-TRANS retinoic acid (ATRA) resistance in breast cancer cells. Tretinoin 101-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 50-58 12595744-2 2002 N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR). Tretinoin 63-67 erb-b2 receptor tyrosine kinase 2 Homo sapiens 113-117 12595744-2 2002 N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR). Tretinoin 63-67 erb-b2 receptor tyrosine kinase 2 Homo sapiens 118-121 14612949-0 2003 HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells. Tretinoin 30-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 14612949-0 2003 HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells. Tretinoin 30-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 5-8 14612949-1 2003 We previously demonstrated that HER2/neu prevents all trans-retinoic acid (ATRA) from inducing growth inhibition in MDA-MB-453 breast cancer cells. Tretinoin 54-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 32-36 14612949-1 2003 We previously demonstrated that HER2/neu prevents all trans-retinoic acid (ATRA) from inducing growth inhibition in MDA-MB-453 breast cancer cells. Tretinoin 54-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-40 14612949-1 2003 We previously demonstrated that HER2/neu prevents all trans-retinoic acid (ATRA) from inducing growth inhibition in MDA-MB-453 breast cancer cells. Tretinoin 75-79 erb-b2 receptor tyrosine kinase 2 Homo sapiens 32-36 14612949-1 2003 We previously demonstrated that HER2/neu prevents all trans-retinoic acid (ATRA) from inducing growth inhibition in MDA-MB-453 breast cancer cells. Tretinoin 75-79 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-40 12595744-7 2002 Combining 4HPR with ATRA may lead to a novel, selective therapeutic or chemopreventive strategy against HER2/NEU-overexpressing breast tumors. Tretinoin 20-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 104-108 12063559-13 2002 These data demonstrate that ATRA and 9cisRA may inhibit HER-2/neu induced aberrant proliferation in part by retarding cell cycle progression, down-regulating HER-2/neu-mediated signal transduction and inducing Bcl-2-dependent apoptosis through a retinoid receptor-mediated mechanism. Tretinoin 28-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 56-65 12149644-0 2002 Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Tretinoin 27-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 12149644-0 2002 Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Tretinoin 27-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 5-8 12149644-0 2002 Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Tretinoin 42-46 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 12149644-0 2002 Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Tretinoin 42-46 erb-b2 receptor tyrosine kinase 2 Homo sapiens 5-8 12149644-2 2002 This suggests that Her2/neu causes breast cancer cells to be resistant to the growth inhibitory effects of ATRA. Tretinoin 107-111 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-27 12149644-5 2002 We then determined whether Her2/neu uses Grb2 and Akt proteins to induce ATRA resistance. Tretinoin 73-77 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-35 12149644-7 2002 When incubated with L-Grb2 or transfected with the DN AKT mutant, ATRA-resistant, Her2/neu-overexpressing cells became sensitive to ATRA. Tretinoin 66-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 82-86 12149644-7 2002 When incubated with L-Grb2 or transfected with the DN AKT mutant, ATRA-resistant, Her2/neu-overexpressing cells became sensitive to ATRA. Tretinoin 132-136 erb-b2 receptor tyrosine kinase 2 Homo sapiens 82-86 12149644-8 2002 Our results indicate that Her2/neu utilizes Grb2 and Akt proteins to induce ATRA resistance in breast cancer cells. Tretinoin 76-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-34 12063559-13 2002 These data demonstrate that ATRA and 9cisRA may inhibit HER-2/neu induced aberrant proliferation in part by retarding cell cycle progression, down-regulating HER-2/neu-mediated signal transduction and inducing Bcl-2-dependent apoptosis through a retinoid receptor-mediated mechanism. Tretinoin 28-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 56-61 12063559-13 2002 These data demonstrate that ATRA and 9cisRA may inhibit HER-2/neu induced aberrant proliferation in part by retarding cell cycle progression, down-regulating HER-2/neu-mediated signal transduction and inducing Bcl-2-dependent apoptosis through a retinoid receptor-mediated mechanism. Tretinoin 28-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-65 9662255-0 1998 Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Tretinoin 11-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-56 9791009-5 1998 All-trans (ATRA) and 9-cis retinoic acid (9cRA) reduce c-erbB-1 protein to 50-100%, c-erbB-2 to 20-30%, and c-erbB-3 to 10-50% of control, depending on the concentration, respectively, without influencing the tyrosine phosphorylation status. Tretinoin 11-15 erb-b2 receptor tyrosine kinase 2 Homo sapiens 84-92 9791009-7 1998 Retinoic acid-mediated down-regulation of growth and c-erbB-2 and -3 expression was also seen in MCF-7 cells. Tretinoin 0-13 erb-b2 receptor tyrosine kinase 2 Homo sapiens 53-68 9791009-8 1998 We conclude that retinoic acids are efficient repressors of c-erbB-2 and -3 gene expression, whereas c-erbB-1 is not markedly affected. Tretinoin 17-31 erb-b2 receptor tyrosine kinase 2 Homo sapiens 60-75 10664247-7 2000 These results reveal that the metastasis-preventing effect of ATRA may partly result from the up-regulation of nm23-H1, and the metastasis-promoting effects of EGF and c-erbB-2/neu were probably mediated in part by the down-regulation of nm23-H1. Tretinoin 62-66 erb-b2 receptor tyrosine kinase 2 Homo sapiens 177-180 10383375-2 1999 Recently, we reported that retinoic acids are efficient repressors of c-erbB-2 and -3, but not of c-erbB-1 gene expresson. Tretinoin 27-41 erb-b2 receptor tyrosine kinase 2 Homo sapiens 70-85 9662255-1 1998 We investigated the effects of all-trans retinoic acid (ATRA) and fenretinide (4-HPR) on c-erbB-2 expression in SK-BR-3, BT-474 and MCF-7 breast cancer cells and on the growth, differentiation, apoptosis and cisplatin (CDDP) sensitivity of SK-BR-3 cells. Tretinoin 41-54 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-97 9662255-1 1998 We investigated the effects of all-trans retinoic acid (ATRA) and fenretinide (4-HPR) on c-erbB-2 expression in SK-BR-3, BT-474 and MCF-7 breast cancer cells and on the growth, differentiation, apoptosis and cisplatin (CDDP) sensitivity of SK-BR-3 cells. Tretinoin 56-60 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-97 7906679-7 1994 Of the agents which inhibit the growth of T47D and ZR75.1 cells--Pg, Prl, cAMP, RA and TPA--only Pg and cAMP caused an increase in the erbB-2 protein level. Tretinoin 80-82 erb-b2 receptor tyrosine kinase 2 Homo sapiens 135-141